The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity
Open accessAbstract
Introduction: Cisplatin, a platinum-based antineoplastic agent, is the cornerstone for the treatment of many malignancies. Nephrotoxicity is the primary dose-limiting toxicity, and various hydration regimens and supplementation strategies are used to prevent cisplatin-induced kidney injury. However, evidence-based recommendations on specific hydration regimens are limited. A systematic review was performed to evaluate clinical studies that have examined hydration and supplementation strategies to prevent cisplatin-induced nephrotoxicity. Materials and Methods: PubMed and Excerpta Medica databases were searched from 1966 through October 2015 for clinical trials and other studies focused on hydration regimens to prevent nephrotoxicity in cancer patients treated with cisplatin. The University of Oxford Centre for Evidence-Based Medicine criteria were used to grade level of evidence. Results: Among the 1,407 identified studies, 24 were included in this systematic review. All studies differed on type, volume, and duration of hydration. Among the 24 studies, 5 evaluated short-duration hydration, 4 evaluated low-volume hydration, 4 investigated magnesium supplementation, and 7 reviewed forced diuresis with hydration. Short-duration and lower-volume hydration regimens are effective in preventing cisplatin-induced nephrotoxicity. Magnesium supplementation may have a role as a nephroprotectant, and forced diuresis may be appropriate in some patients receiving cisplatin. Conclusion: Hydration is essential for all patients to prevent cisplatin-induced nephrotoxicity. Specifically, short-duration, low-volume, outpatient hydration with magnesium supplementation and mannitol forced diuresis (in select patients) represent best practice principles for the safe use of cisplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Bellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L., Palevsky, P., & workgroup, T. A. (2004) · Critical Care · doi:10.1186/cc2872 · Cited by 6,781
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
LOEHRER, P. J., & EINHORN, L. H. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-5-704 · Cited by 947
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresis
Hayes, D. M., Cvitkovic, E., Golbey, R. B., Scheiner, E., Helson, L., & Krakoff, I. H. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j · Cited by 626
Madias, N. E., & Harrington, J. T. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90825-2 · Cited by 453
Nephrotoxicity and Hydration Management for Cisplatin, Carboplatin, and Ormaplatin
Cornelison, T. L., & Reed, E. (1993) · Gynecologic Oncology · doi:10.1006/gyno.1993.1184 · Cited by 270
Lajer, H., & Daugaard, G. (1999) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0097 · Cited by 250
Cisplatin nephrotoxicity: A review
Daugaard, G., & Abildgaard, U. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00694330 · Cited by 234
Clinical trials of cis-diamminedichloroplatinum (NSC-119875).
Lippman, A. J., Helson, C., Helson, L., & Krakoff, I. H. (1973) · PubMed · Cited by 133
Yokoo, K., Murakami, R., Matsuzaki, T., Yoshitome, K., Hamada, A., & Saito, H. (2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0215-1 · Cited by 64
Horinouchi, H., Kubota, K., Itani, H., Taniyama, T. K., Nakamichi, S., Wakui, H., Kanda, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt122 · Cited by 63
Muraki, K., Koyama, R., Honma, Y., Yagishita, S., Shukuya, T., Ohashi, R., Takahashi, F., Kido, K., Iwakami, S., Sasaki, S., et al. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.10.16 · Cited by 62
Yamamoto, Y., Watanabe, K., Tsukiyama, I., Matsushita, H., Yabushita, H., Matsuura, K., & Wakatsuki, A. (2015) · PubMed · Cited by 51
Oka, T., Kimura, T., Suzumura, T., et al. (2014) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-15-70 · Cited by 47
Cited by
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Volarevic, V., Djokovic, B., Jankovic, M. G., Harrell, C. R., Fellabaum, C., Djonov, V., & Arsenijevic, N. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0518-9 · Cited by 438
Natural products: potential treatments for cisplatin-induced nephrotoxicity
Fang, C.-Y., Lou, D.-Y., Zhou, L.-Q., Wang, J.-C., Yang, B., He, Q.-J., Wang, J.-J., & Weng, Q.-J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00620-9 · Cited by 397
Romani, A. M. P. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115323 · Cited by 383
Myricetin: A review of the most recent research
Song, X., Tan, L., Wang, M., Ren, C., Guo, C., Yang, B., Ren, Y., Cao, Z., Li, Y., & Pei, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111017 · Cited by 378
Metadata
- Authors
- Crona, D. J., Faso, A., Nishijima, T. F., McGraw, K. A., Galsky, M. D., & Milowsky, M. I.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04-24
- Volume
- 22
- Issue
- 5
- Pages
- 609-619
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2610082023
- Cited by
- 395
- References
- 17
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.